Aprea Share Price

Aprea Share Price

NASDAQ: APRE | Healthcare
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Aprea Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
N/A
Volume
N/A
Average Traded
N/A

Aprea Share Price Chart

Line chart of the Aprea price trend over the selected period. The price rose overall, ranging from 0.22 to 0.46, ending at 0.23.
$0.00$0.00
L
Show Current Price
H

Aprea Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.00
Revenue (TTM)
$290.00M
Return On Equity (TTM)
-41.47%
Profit Margin
-4344.83%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-95.53%

Aprea Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$2.46-$3.29-$3.59-$4.81
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-33.74%-9.12%-33.98%

Aprea Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.58$1.50$0.29
Net Profit-$112.66-$14.29-$12.96-$12.60
Net Profit MarginN/A-2463.79%-864.00%-4344.83%
Income ChangeN/A87.32%9.31%2.78%

Aprea Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets0.370.40.130.0
Current Assets15.5623.5822.5230.15
Total Assets15.9323.9822.6530.16
Non Current Liabilities0.00.00.00.0
Current Liabilities2.763.364.393.2
Total Liabilities2.763.364.393.2
Shareholders' Equity12.4419.3116.9525.64

Aprea Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-12.89-13.56-12.18-25.01
Investing0.0-0.02-0.090.0
Financing4.6414.825.140.68

Corporate Actions

Split
Ex-date: 13 Feb 2023

Split
Ex-date: 27 Dec 2018

About Aprea

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Aprea Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %

Aprea Share Price FAQs